Evidence map›Paper›PMID 30293770›Full record

Trial reportLancet (London, England)2018

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.

Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins and 1 more

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Lancet (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06606821 (The Effects of Tirzepatide on Coronary Plaque Lipid Content and Myocardial Microvascular Function in Overweight and Obese People With Coronary Disease - The IDEAL-COR Study), which is not on this map. Cited by 392 papers, 23 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
392citing papers in PubMed, 23 pooled it
52.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06606821 phase4recruitingstarted 2024, after this paper: background citation

The Effects of Tirzepatide on Coronary Plaque Lipid Content and Myocardial Microvascular Function in Overweight and Obese People With Coronary Disease - The IDEAL-COR Study

Ran2024Enrolled124Registered outcomes23Posted comparisons0ConditionsAtherosclerosis Cardiovascular Disease, Chronic Coronary Artery Disease, Coronary Artery Disease, Coronary Microvascular DysfunctionArmsPlacebo, Tirzepatide
PMID 27295427PMID 30473097PMID 27633186PMID 35658024PMID 34170647PMID 20061546PMID 26685971PMID 26242984PMID 23288155PMID 21525448PMID 30291013PMID 18188451other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

392 citing papers in PubMed, 23 syntheses or guidelines pooled it, 774 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Effect of Tirzepatide on arrhythmic, major cardiovascular, and neurological outcomes in patients with type 2 diabetes: A systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025 · on this map
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

332 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Juan Pablo FriasNational Research Institute, Los Angeles, CA, USA.
Michael A NauckDiabetes Center Bochum-Hattingen, St Josef Hospital, Ruhr-University Bochum, Bochum, Germany.
Joanna VanDiabetes Research Center, Tustin, CA, USA.
Mark E KutnerSuncoast Research Group, LLC, Miami, FL, USA.
Xuewei CuiEli Lilly and Company, Indianapolis, IN, USA.
Charles BensonEli Lilly and Company, Indianapolis, IN, USA.
Shweta UrvaEli Lilly and Company, Indianapolis, IN, USA.
Ruth E GimenoEli Lilly and Company, Indianapolis, IN, USA.
Zvonko MilicevicEli Lilly and Company, Vienna, Austria.
Deborah RobinsEli Lilly and Company, Indianapolis, IN, USA.
Axel HauptEli Lilly and Company, Indianapolis, IN, USA. Electronic address: haupt_axel@lilly.com.
Eli Lilly (United States) · USDiabetes Care Center · USNational Research Institute · USSt. Josef-Hospital · DESuncoast Clinical Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLY3298176 is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. We aimed to examine the efficacy and safety of co-stimulation of the GLP-1 and GIP receptors with LY3298176 compared with placebo or selective stimulation of GLP-1 receptors with dulaglutide in patients with poorly controlled type 2 diabetes.

methodsIn this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks. Assignment was stratified by baseline glycated haemoglobin A

findingsBetween May 24, 2017, and March 28, 2018, 555 participants were assessed for eligibility, of whom 318 were randomly assigned to one of the six treatment groups. Because two participants did not receive treatment, the modified intention-to-treat and safety populations included 316 participants. 258 (81·7%) participants completed 26 weeks of treatment, and 283 (89·6%) completed the study. At baseline, mean age was 57 years (SD 9), BMI was 32·6 kg/m

interpretationThe dual GIP and GLP-1 receptor agonist, LY3298176, showed significantly better efficacy with regard to glucose control and weight loss than did dulaglutide, with an acceptable safety and tolerability profile. Combined GIP and GLP-1 receptor stimulation might offer a new therapeutic option in the treatment of type 2 diabetes.

fundingEli Lilly and Company.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsBlood GlucoseDiabetes Mellitus, Type 2Double-Blind MethodDrug Administration ScheduleFemaleGastric Inhibitory PolypeptideGlucagon-Like PeptidesGlycated HemoglobinHumansHypoglycemic AgentsImmunoglobulin Fc FragmentsMaleMiddle AgedRecombinant Fusion ProteinsTirzepatideBlood GlucosedulaglutideGastric Inhibitory PolypeptideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsTirzepatide

Identifiers

PMID30293770
OpenAlexW2895666357

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.